Searched for: in-biosketch:true
person:golfij01
Postoperative sinus thrombosis in the setting of skull base surgery [Meeting Abstract]
Benjamin, C G; Sen, R; Pacione, D; Golfinos, J; Sen, C; Roland, J T; McMenomey, S
Objective: Cerebral venous sinus thrombosis (CVST) is a rare but potentially dangerous complication following craniotomies involving the posterior fossa, the skull base, and craniotomies involving the superior sagittal sinus. Surgical manipulation of the sinuses has been shown to cause sinus thromboses of varying degrees. This phenomenon is often clinically silent, with only a small number of patients becoming symptomatic. Recent advances in neuroimaging provide higher resolution evaluation of cerebral sinuses pre and postoperatively, often revealing clinically silent filling defects. Although sinus thrombosis can be a major cause of morbidity and mortality, its incidence and factors that contribute to its formation in the postoperative population remain unclear. In addition, current guidelines advise to anticoagulate with Heparin upon diagnosis, which can be contraindicated for immediate post craniotomy patients. The goal of this study is to evaluate retrospective data of patient outcomes and factors that might contribute to sinus thrombus formation. Methods: A retrospective chart review was conducted at NYU Langone Medical Center. Ninety-seven patients were included who underwent either a retrosigmoid/translabrynthine/suboccipital resection of a posterior fossa tumor or a supratentorial craniotomy for resection of parasagittal/falcine tumor between July 1, 2014 and July 1, 2015. Pre operative Magnetic Resonance Venography (MRV) was obtained per the attending surgeon's discretion. Based on intraoperative findings, clinical symptoms, and surgeon's preference, a postoperative MRV was obtained. Decision to treat a thrombosis was made based on the results of the MRV and clinical symptoms. Treatments included observation, intravenous fluids (IVF) alone, anti-platelet therapy with Aspirin alone, or a combination of the two. Results: A total of 7 of 97 patients (7.22%) had postoperative sinus thrombosis. Of those patients, 5 had occlusion of the venous sinuses. In the occlusion group, 4 had preoperative imaging documenting patency of the sinuses. An additional 2 patients had postoperative MRVs revealing partial thrombosis of the sinus, 1 that was new and 1 that did not have a preoperative MRV for comparison. Compared with the cohort of patients without postoperative thromboses, there was no significant difference in age, BMI, length of surgery, or surgical approach. Of the 5 patients with postoperative thrombotic occlusion, 4 underwent intervention (1 with IVF alone, 2 with IVF and aspirin, and 1 with aspirin alone). Two patients with thromboses also developed CSF leaks requiring lumbar drainage and operative repair. One patient had a persistent CSF leak requiring a shunt. Of the 2 patients with partial thrombosis, 1 was placed on IVF and aspirin. At 3 months follow up, 1 out of 5 patients in the occlusion group had recanalization of the previously thrombosed sinus. Conclusions: MRV is a non-invasive method to evaluate the caliber and patency of dural venous sinuses in post craniotomy patients. Symptomatic thrombosis is rare and can be managed either conservatively or with IVF and/or anti platelet therapy, both which are safer than anticoagulation with heparin in post craniotomy patients. A larger prospective trial is necessary to further characterize the incidence of postoperative venous sinus thrombosis, identify risk factors, and to devise recommendations for therapy
EMBASE:72235346
ISSN: 2193-634x
CID: 2094672
A matched cohort comparison of clinical outcomes following microsurgical resection or stereotactic radiosurgery for patients with small- and medium-sized vestibular schwannomas
Golfinos, John G; Hill, Travis C; Rokosh, Rae; Choudhry, Osamah; Shinseki, Matthew; Mansouri, Alireza; Friedmann, David R; Thomas Roland, J Jr; Kondziolka, Douglas
OBJECTIVE A randomized trial that compares clinical outcomes following microsurgery (MS) or stereotactic radiosurgery (SRS) for patients with small- and medium-sized vestibular schwannomas (VSs) is impractical, but would have important implications for clinical decision making. A matched cohort analysis was conducted to evaluate clinical outcomes in patients treated with MS or SRS. METHODS The records of 399 VS patients who were cared for by 2 neurosurgeons and 1 neurotologist between 2001 and 2014 were evaluated. From this data set, 3 retrospective matched cohorts were created to compare hearing preservation (21 matched pairs), facial nerve preservation (83 matched pairs), intervention-free survival, and complication rates (85 matched pairs) between cases managed with SRS and patients managed with MS. Cases were matched for age at surgery (+/- 10 years) and lesion size (+/- 0.1 cm). To compare hearing outcomes, cases were additionally matched for preoperative Class A hearing according to the American Academy of Otolaryngology-Head and Neck Surgery guidelines. To compare facial nerve (i.e., cranial nerve [CN] VII) outcomes, cases were additionally matched for preoperative House-Brackmann (HB) score. Investigators who were not involved with patient care reviewed the clinical and imaging records. The reported outcomes were as assessed at the time of the last follow-up, unless otherwise stated. RESULTS The preservation of preoperative Class A hearing status was achieved in 14.3% of MS cases compared with 42.9% of SRS cases (OR 4.5; p < 0.05) after an average follow-up interval of 43.7 months and 30.3 months, respectively. Serviceable hearing was preserved in 42.8% of MS cases compared with 85.7% of SRS cases (OR 8.0; p < 0.01). The rates of postoperative CN VII dysfunction were low for both groups, although significantly higher in the MS group (HB III-IV 11% vs 0% for SRS; OR 21.3; p < 0.01) at a median follow-up interval of 35.7 and 19.0 months for MS and SRS, respectively. There was no difference in the need for subsequent intervention (2 MS patients and 2 SRS patients). CONCLUSIONS At this high-volume center, VS resection or radiosurgery for tumors = 2.8 cm in diameter was associated with low overall morbidity. The need for subsequent intervention was the same in both groups. SRS was associated with improved hearing and facial preservation rates and reduced morbidity, but with a shorter average follow-up period. Facial function was excellent in both groups. Since patients were not randomly selected for surgery, different clinical outcomes may be of different value to individual patients. Both anticipated medical outcomes and patient goals remain the drivers of treatment decisions.
PMID: 27035174
ISSN: 1933-0693
CID: 2059352
Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases
Wolf, Amparo; Zia, Sayyad; Verma, Rashika; Pavlick, Anna; Wilson, Melissa; Golfinos, John G; Silverman, Joshua S; Kondziolka, Douglas
The aim of this study was to evaluate the impact of BRAF inhibitors on survival outcomes in patients receiving stereotactic radiosurgery (SRS) for melanoma brain metastases. We prospectively collected treatment parameters and outcomes for 80 patients with melanoma brain metastases who underwent SRS. Thirty-five patients harbored the BRAF mutation (BRAF-M) and 45 patients did not (BRAF-WT). Univariate and multivariate analyses were performed to identify predictors of overall survival. The median overall survival from first SRS procedure was 6.7, 11.2 months if treated with a BRAF inhibitor and 4.5 months for BRAF-WT. Actuarial survival rates for BRAF-M patients on an inhibitor were 54 % at 6 months and 41 % at 12 months from the time of SRS. In contrast, BRAF-WT had overall survival rates of 28 % at 6 months and 19 % at 12 months. Overall survival was extended for patients on a BRAF inhibitor at or after the first SRS. The median time to intracranial progression was 3.9 months on a BRAF inhibitor and 1.7 months without. The local control rate for all treated tumors was 92.5 %, with no difference based on BRAF status. Patients with higher KPS, fewer treated intracranial metastases, controlled systemic disease, RPA Class 1 and BRAF-M patients had extended overall survival. Overall, patients with BRAF-M treated with both SRS and BRAF inhibitors, at or after SRS, have increased overall survival from the time of SRS. As patients live longer as a result of more effective systemic and local therapies, close surveillance and early management of intracranial disease with SRS will become increasingly important.
PMID: 26852222
ISSN: 1573-7373
CID: 2044642
Concurrent functional and metabolic assessment of brain tumors using hybrid PET/MR imaging
Sacconi, B; Raad, R A; Lee, J; Fine, H; Kondziolka, D; Golfinos, J G; Babb, J S; Jain, R
To evaluate diagnostic accuracy of perfusion weighted imaging (PWI) and positron emission tomography (PET) using an integrated PET/MR system in tumor grading as well as in differentiating recurrent tumor from treatment-induced effects (TIE) in brain tumor patients. Twenty patients (Group A: treatment naive, 9 patients with 16 lesions; Group B: post-therapy, 11 patients with 18 lesions) underwent fluorine 18 (18F) fluorodeoxyglucose (FDG) brain PET/MR with PWI. Two blinded readers predicted low versus high-grade tumor (for Group A) and tumor recurrence versus TIE (for Group B) based solely on tumor rCBV (regional cerebral blood volume) and SUV (standardized uptake values). Tumor histopathology at resection was the reference standard. Using rCBVmean = 1.74 as a cut-off, 100 % sensitivity and 74 % specificity were observed, whereas 75 % sensitivity and 89.7 % specificity were observed with SUVmean = 4.0 as a cut-off to classify patients as test positive for low-grade tumors (Group A) and TIE (Group B). Diagnostic accuracy for detection of low-grade tumors was 90 % using PWI and 40 % using PET in Group A (p = 0.056); for detection of TIE in Group B, diagnostic accuracy was 94.1 % using PWI and 55.6 % using PET (p = 0.033). No significant correlation was demonstrated between rCBV parameters and SUV in Group A (mean values: p > 0.403), Group B (p > 0.06) and in the entire population (p > 0.07). Best overall sensitivity and specificity were obtained using rCBVmean = 1.74 and SUVmean = 4.0 cut-off values. PWI demonstrated better diagnostic accuracy in both groups. Poor correlation was observed between FDG and rCBV parameters.
PMID: 26729270
ISSN: 1573-7373
CID: 1901082
EFFECTS OF EVEROLIMUS ON MENINGIOMA GROWTH IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2 [Meeting Abstract]
Osorio, Diana; Filatov, Alexander; Hagiwara, Mari; Mitchell, Carole; Wisoff, Jeffrey; Golfinos, John; Roland, J. Thomas; Allen, Jeffrey; Karajannis, Matthias
ISI:000361304800159
ISSN: 1522-8517
CID: 2964282
Defining glioblastoma stem cell heterogeneity [Meeting Abstract]
Bayin, N S; Sen, R; Si, S; Modrek, A S; Ortenzi, V; Zagzag, D; Snuderl, M; Golfinos, J G; Doyle, W; Galifianakis, N; Chesler, M; Illa-Bochaca, I; Barcellos-Hoff, M H; Dolgalev, I; Heguy, A; Placantonakis, D
A major impeding factor in designing effective therapies against glioblastoma (GBM) is its extensive molecular heterogeneity and the diversity of microenvironmental conditions within any given tumor. To test whether heterogeneity with the GBM stem cell (GSC) population is required to ensure tumor growth in such diverse microenvironments, we used human GBM biospecimens to examine the identity of cells marked by two established GSC markers: CD133 and activation of the Notch pathway. Using primary GBM cultures engineered to express GFP upon activation of Notch signaling, we observed only partial overlap between cells expressing cell surface CD133 and cells with Notch activation (n = 3 specimens), contrary to expectations based on prior literature. To further investigate this finding, we FACS-isolated these cell populations and characterized them. While both CD133+ (CD133 + /Notch-) and Notch+(CD133-/Notch+) cells fulfill GSC criteria, they differ vastly in their transcriptome, metabolic preferences and differentiation capacity, thus giving rise to histologically distinct tumors. CD133+ GSCs have increased expression of hypoxia-regulated and glycolytic genes, and are able to expand under hypoxia by activating anaerobic glycolysis. In contrast, Notch+ GSCs are unable to utilize anaerobic glycolysis under hypoxia, leading to decreased tumorsphere formation ability. While CD133+ GSCs give rise to histologically homogeneous tumors devoid of large tumor vessels, tumors initiated by Notch+ GSCs are marked by large perfusing vessels enveloped by pericytes. Using a lineage tracing system, we showed that pericytes are derived from Notch+ GSCs. In addition, Notch+ cells are able to give rise to all tumor lineages in vitro and in vivo, including CD133 + /Notch- cells, as opposed to Notch- populations, which have restricted differentiation capacity and do not generate Notch+ lineages. Our findings demonstrate that GSC heterogeneity is a mechanism used by tumors to sustain growth in diverse microenvironmental conditions
EMBASE:72188944
ISSN: 1522-8517
CID: 2015952
Dose-Response Relationships for Meningioma Radiosurgery
Sethi, Rajni A; Rush, Stephen C; Liu, Shian; Sethi, Suresh A; Parker, Erik; Donahue, Bernadine; Narayana, Ashwatha; Silverman, Joshua; Kondziolka, Douglas; Golfinos, John G
OBJECTIVE: Dose-response relationships for meningioma radiosurgery are poorly characterized. We evaluated determinants of local recurrence for meningiomas treated with Gamma Knife radiosurgery (GKRS), to guide future treatment approaches to optimize tumor control. MATERIALS AND METHODS: A total of 101 consecutive patients (108 tumors) who underwent GKRS for benign, atypical, or malignant meningiomas between 1998 and 2011 were studied. Local recurrence was assessed. Cox proportional hazards and logistic regression analyses were used to determine the association of patient-related, tumor-related, and treatment-related characteristics with local recurrence. Acute and late toxicity was evaluated. RESULTS: World Health Organization (2007 classification) tumor grade was I (82%), II (11%), or III (7%). Median dose was 14 Gy (range, 10 to 18 Gy) for grade I tumors and 16 Gy (range, 12 to 20 Gy) for grade II and III tumors. Median follow-up was 25 months (maximum, 17 y). Two- /5-year actuarial local control rates were 100%/98% for grade I tumors and 76%/56% for grade II/III tumors. Higher tumor grade and lower GKRS dose were associated with local failure. In this cohort, there was a 42% relative reduction in local recurrence for each 1 Gy of dose escalation. CONCLUSIONS: Treatment was well tolerated with no moderate or severe toxicity. Tumor control was excellent in benign tumors and suboptimal in higher grade tumors. Because the main determinant of local recurrence was GKRS dose, we recommend dose escalation for atypical or malignant tumors to doses between 16 and 20 Gy where critical structures allow.
PMID: 26595685
ISSN: 1537-453x
CID: 1856322
Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis
Weiss, Sarah; Darvishian, Farbod; Tadepalli, Jyothi; Shapiro, Richard; Golfinos, John; Pavlick, Anna; Polsky, David; Kirchhoff, Tomas; Osman, Iman
BACKGROUND: Median overall survival (OS) of patients with melanoma brain metastases (MBM) is usually 6 months or less. There are rare reports of patients with treated MBM who survived for years. These outlier cases represent valuable opportunities to study the somatic and germline factors that may have influenced patient outcome and led to extended survival. CASE PRESENTATION: Here we report the clinical scenario of a 67 year old man with a recurrent brain metastasis from melanoma who has survived over 12 years post-resection. We review the literature relating to clinical and molecular variables associated with long term survival post-brain metastasis. We present the somatic characteristics of this individual patient's tumor as well as an analysis of inherited genetic variants related to immune function. The patient's resected brain tumor is BRAF V600E mutated, NRAS wild type (WT), and TERT C250T mutated. The patient is a carrier of germline variants in immunomodulatory loci associated with prolonged survival. CONCLUSIONS: Our data suggest that genetic variants in immunomodulatory loci may partially contribute to this patient's unusually favorable outcome and should not be overlooked. With further and future investigation, knowledge of inherited single nucleotide polymorphisms (SNPs) may provide clinicians with more individualized prognostic information for melanoma patients, with potential implications for surveillance strategies and therapeutic interventions.
PMCID:4657192
PMID: 26597176
ISSN: 1471-2407
CID: 1856342
Resection Followed by Involved-Field Fractionated Radiotherapy in the Management of Single Brain Metastasis
Shin, Samuel M; Vatner, Ralph E; Tam, Moses; Golfinos, John G; Narayana, Ashwatha; Kondziolka, Douglas; Silverman, Joshua Seth
INTRODUCTION: We expanded upon our previous experience using involved-field fractionated radiotherapy (IFRT) as an alternative to whole brain radiotherapy or stereotactic radiosurgery for patients with surgically resected brain metastases (BM). MATERIALS AND METHODS: All patients with single BM who underwent surgical resection followed by IFRT at our institution from 2006 to 2013 were evaluated. Local recurrence (LR)-free survival, distant failure (DF)-free survival, and overall survival (OS) were determined. Analyses were performed associating clinical variables with LR and DF. Salvage approaches and toxicity of treatment for each patient were also assessed. RESULTS: Median follow-up was 19.1 months. Fifty-six patients were treated with a median dose of 40.05 Gy/15 fractions with IFRT to the resection cavity. LR-free survival was 91.4%, DF-free survival was 68.4%, and OS was 77.7% at 12 months. No variables were associated with increased LR; however, melanoma histopathology and infratentorial location were associated with DF on multivariate analysis. LRs were salvaged in 5/8 patients, and DFs were salvaged in 24/29 patients. Two patients developed radionecrosis. CONCLUSION: Adjuvant IFRT is feasible and safe for well-selected patients with surgically resected single BM. Acceptable rates of local control and salvage of distal intracranial recurrences continue to be achieved with continued follow-up.
PMCID:4585114
PMID: 26442218
ISSN: 2234-943x
CID: 1793122
Immunologic profile of melanoma brain metastases (MBM) in patients (pts) with prolonged survival [Meeting Abstract]
Lui, Kevin P; Silva, Ines EDPires; Weiss, Sarah Ann; Han, Sung Won; Darvishian, Farbod; Pavlick, Anna C; Golfinos, John; Moogk, Duane; Krogsgaard, Michelle; Osman, Iman
ISI:000358036901980
ISSN: 1527-7755
CID: 1729542